Memphis Pharmaceuticals results, Q1 2022
Net profit, assets, equity and cash flow for Q1 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit-4.42 millionEGP
Total assets437 millionEGP
Shareholders' equity-43.6 millionEGP
Operating cash flow2.14 millionEGP
In short
- Memphis Pharmaceuticals's net profit for Q1 2022 was about -4.42 million EGP.
- Total assets at the end of Q1 2022 were about 437 million EGP, and shareholders' equity about -43.6 million EGP.
- Operating cash flow for Q1 2022 was positive at 2.14 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit-4.42 million——
Gross profit27.34 million——
Total assets437 million——
Total liabilities481 million——
Shareholders' equity-43.6 million——
Total liabilities and equity437 million——
Operating cash flow2.14 million——
Investing cash flow1.24 million——
Financing cash flow———
Net change in cash3.38 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy